14 completed, 8 recruiting, 5 unknown, 4 terminated. 34 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 34 | Completed 14, Recruiting 8, Unknown 5, Terminated 4, Active not recruiting 2, Withdrawn 1 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia Momelotinib, Azacitidine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 | 2026-03-19 | 2026-03-27 |
| Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined Tagraxofusp, Pacritinib - Myelofibrosis，MF | Early Phase 1 | Recruiting | University of Kansas Medical Center | 20 | 2025-08-25 | 2026-05-06 |
| CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases CD7 CAR-T cells injection, Allo-HSCT - Bone Marrow Failure Syndrome | Early Phase 1 | Recruiting | Zhejiang University | 20 | 2025-01-31 | 2025-01-22 |
| CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial Autologous CAR123 T lymphocytes - Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma | Early Phase 1 | Active not recruiting | Institute of Hematology and Blood Transfusion, Czech Republic | 18 | 2024-10-23 | 2026-09-14 |
| CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation - Aplastic Anemia | Early Phase 1 | Recruiting | Zhejiang University | 30 | 2024-10-20 | 2024-10-09 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes NCR300 - Relapsed / Refractory Myelodysplastic Syndromes | Early Phase 1 | Unknown | Nuwacell Biotechnologies Co., Ltd. | 15 | 2022-05-30 | 2022-05-12 |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation IFN-γ (interferon gamma-1b) injection - Myelodysplastic Syndromes, Myeloid Leukemia | Early Phase 1 | Completed | Sawa Ito, MD | 8 | 2021-03-08 | 2025-04-29 |
| 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies 5-azacytidine, Decitabine - Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes | Early Phase 1 | Recruiting | Benjamin Tomlinson | 20 | 2020-11-16 | 2026-05-18 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| TPO-Mimetic Use in Children for Hematopoietic Failure Romiplostim - Bone Marrow Failure Disorders, Aplastic Anemia | Early Phase 1 | Completed | Anjali Sharathkumar | 15 | 2020-08-18 | 2024-07-30 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant Hyperbaric oxygen - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Omar Aljitawi | 24 | 2020-07-01 | 2026-06-03 |
| CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia Continuous Positive Airway Pressure, Patient Observation, Questionnaire Administration - CALR Gene Mutation, Essential Thrombocythemia | Early Phase 1 | Terminated | University of Utah | 8 | 2019-05-15 | 2024-01-08 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CD123-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2019-11-12 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CLL1-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2021-05-19 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Primary Myelofibrosis, Secondary Myelofibrosis | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2018-01-31 | 2020-10-14 |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia Nilotinib 150 MG [Tasigna], Imatinib 400mg - Chronic Myeloid Leukemia | Early Phase 1 | Unknown | Assiut University | 100 | 2017-12-01 | 2017-10-10 |
| Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers Trivalent Influenza Vaccine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Early Phase 1 | Completed | Roswell Park Cancer Institute | 130 | 2017-10-17 | 2023-06-06 |
| Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Pembrolizumab - Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma | Early Phase 1 | Completed | University of Chicago | 12 | 2017-03-07 | 2024-04-22 |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Bone Marrow Aspiration and Biopsy, Laboratory Biomarker Analysis, Siltuximab - Myelofibrosis, Polycythemia Vera | Early Phase 1 | Withdrawn | Northwestern University | 2016-06-01 | 2016-10-24 |
Showing 20 of 34. Sign in to see all of them.
Myelodysplastic Syndromes (19) · Leukemia, Myeloid, Acute (12) · Primary Myelofibrosis (9) · Leukemia (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Lymphoma, Non-Hodgkin (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Hematologic Neoplasms (5) · Hodgkin Disease (5) · Anemia, Aplastic (4) · Bone Marrow Failure Disorders (4) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma (4) · Multiple Myeloma (4) · Myeloproliferative Disorders (4)
Hematologic Diseases (34) · Hemic and Lymphatic Diseases (33) · Neoplasms by Histologic Type (21) · Neoplasms (20) · Immune System Diseases (13) · Leukemia (13) · Leukemia, Myeloid (13) · Myeloproliferative Disorders (12) · Immunoproliferative Disorders (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Chronic Disease (10) · Disease Attributes (10) · Lymphatic Diseases (10)
Azacitidine (2) · Cord Blood Stem Cell Transplantation (2) · Cyclophosphamide (2) · Cytarabine (2) · Mycophenolic Acid (2) · Stem Cell Transplantation (2) · Transplantation (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Arsenic Trioxide (1) · Biopsy (1) · Bortezomib (1) · Continuous Positive Airway Pressure (1) · Contrast Media (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Children's Hospital of Philadelphia (2) · Northwestern University (2) · University of Kansas Medical Center (2) · Zhejiang University (2) · iCell Gene Therapeutics (2) · Anjali Sharathkumar (1) · Assiut University (1) · Benjamin Tomlinson (1) · Case Comprehensive Cancer Center (1) · Children's Hospital Medical Center, Cincinnati (1) · Institute of Hematology and Blood Transfusion, Czech Republic (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (25) · China (4) · Australia (1) · Czechia (1)
Fang Liu, MD, PhD (2) · He Huang, MD (2) · Hongyu Zhang, MD, PhD (2) · Timothy Olson, MD, PhD (2) · Abdulraheem Yacoub, Doctor of Medicine (1) · Amanda Cashen, M.D. (1) · Anjali A. Sharathkumar, MBBS, MD, MS (1) · B. Douglas Smith, MD (1) · Benjamin H Tomlinson, Tomlinson (1) · Brady Stein, MD (1) · Candido E. Rivera, M.D. (1) · Christian B Gocke, MD, PhD (1) · Elizabeth A Griffiths (1) · Gail Roboz, MD (1) · Jan Vydra, MD, PhD (1)
P30CA006973 (1), P30CA015083 (1), P30CA016672 (1), P30CA042014 (1), P30CA043703 (1), P30CA060553 (1), P30CA072720 (1)